Fundraising Fox
🦊/Companies
Sign in

Gero

Founded 2018 · 137 employees on LinkedIn · 1 known investors

Find your way into Gero

101 people in our graph share verified history with the Gero team — schools, employers, funds. One of them is your warm intro.

Damien van der Bijlunlockedknows Peter Fedichev · together at University of Amsterdam (overlapped)
×6knows the team · via University of Amsterdam
×4knows the team · via Moscow Institute of Physics and Technology (State University) (MIPT)
knows the team · via AMOLF

Gero is a biotech company applying AI, data science, and physics-based models of human health to discover drug targets and therapies for aging and age-related chronic diseases. It develops a therapeutic pipeline using longitudinal health data, statistical genetics, and multi-omics.

AI & Machine LearningBiotechLongevity

Founders & leadership

Gero was founded in 2018 by Peter Fedichev and Max.

PFPeter Fedichev
Peter Fedichevin𝕏Co-founder & CEOPeter Fedichev holds an M.S. in theoretical physics from the Moscow Institute of Physics and Technology and a Ph.D. from the University of Amsterdam, with research experience in condensed matter physics and biophysics at institutions including the Kurchatov Institute, University of Amsterdam, FOM institute AMOLF, and University of Innsbruck. He is co-founder and CEO of Gero, a biotech company developing AI and physics-based models to identify drug targets and therapies for aging and age-related diseases.
MMax
Maxin𝕏Co-founderMax is co-founder of Gero, a biotech company that applies AI and physics-based models to drug discovery for aging and age-related diseases, and also co-founded Quantum Pharmaceuticals, which focuses on drug discovery through molecular modeling. He leads business development at Gero.

Investors · 1

Melnichek InvestmentsLimassol

Funding

SEC filings, press & company announcements

$17M disclosed across 1 of 2 rounds · 2023–2026

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 3

by search overlap
SoundCloud4 shared keywordsAudio distribution and music-sharing platform for artists and creators.
Genius4 shared keywordsGenius is a crowdsourced music encyclopedia where a community of contributors annotates and discusses song lyrics, artist information, and music culture across all genres. The platform serves artists, creatives, and music fans who want to explore and share deeper context about music and its creators.
Lifespan3 shared keywordsLifespan Research Institute invests in biotechnology startups developing regenerative medicine and longevity therapies. The institute funds companies working on age-related disease treatment, including cellular senescence, tissue damage repair, and cancer therapeutics.

Companies competing with Gero for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Gero Raises $17 Million To Slow Agingpulse2.com · Jun 2026Gero Raises New Funding, Bringing Total Equity Capital to $34 Million to Advance AI-Driven Aging Drug Discovery Platform | citybizcitybiz.co · Jun 2026Gero Raises $34M for AI Aging Drug Discoveryallsci.com · Jun 2026Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicinesbusinesswire.com · Jun 2026Gero Raises $17M in New Fundingfinsmes.com · Jun 2026Physics-Powered GenAI Biotech Gero Raises $6M to Find Root Causes of Aging and Age-Related Diseasesbusinesswire.com · Oct 2023

Frequently asked questions

What does Gero do?
Gero is a biotech company applying AI, data science, and physics-based models of human health to discover drug targets and therapies for aging and age-related chronic diseases. It develops a therapeutic pipeline using longitudinal health data, statistical genetics, and multi-omics.
Who founded Gero?
Gero was founded by Peter Fedichev, Max in 2018.
Who are Gero's investors?
Gero's investors include Melnichek Investments.
How much funding has Gero raised?
Gero has disclosed $17M raised across 1 of its 2 known rounds.